ImetelChat

A potential date to look forward to.... as we certainly should be expecting to have data submitted...

http://www.hematology.org/Annual-Meetin ... /2853.aspx
Acceptance/Rejection Notification
Notification regarding acceptance or rejection of abstracts will be sent to the presenting author in early-October 2017 by email; consequently, an accurate email address is critical. If your abstract is accepted, the email will specify whether it is accepted as plenary, oral, or poster presentation or whether it has been selected to be published online only. If you have not received an email notification by October 2, 2017, contact

Actually the date to look forward to is Nov 1st when the abstracts are made public. No comments can be made until after they are presented at ASH in December. We pretty much know that MDS data on the first 30 patients will be presented. Beyond that we have no inkling. I am hoping that Dr. T will update the pilot study results but he no longer has control over that data. I am also hoping we might hear from Dr. Lane's lab and certainly Janssen re the combo AML studies in animals. There probably will be nothing on the ongoing R/R study in MF which would be very disappointing but expected at least by me. bp

Geron to Present at the Cantor Fitzgerald Healthcare Conference
MENLO PARK, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the Cantor Fitzgerald Global Healthcare Conference in New York at 1:40 p.m. Eastern Time on Tuesday, September 26, 2017.

A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website and at http://wsw.com/webcast/cantor6/gern/. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.